Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"PIQD: The Once a Day Protease Inhibitor Regimens." Ritonavir Boosted Atazanavir vs. Ritonavir Boosted Fosamprenavir Used in Combination With Tenofovir and Emtricitabine in HIV-1 Infected Antiretroviral Treatment-Naïve Patients.

NCT00242216 is registered in ClinicalTrials.gov with The University of Texas Health Science Center, Houston as lead sponsor.

NCT NCT00242216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00242216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"PIQD: The Once a Day Protease Inhibitor Regimens." Ritonavir Boosted Atazanavir vs. Ritonavir Boosted Fosamprenavir Used in Combination With Tenofovir and Emtricitabine in HIV-1 Infected Antiretroviral Treatment-Naïve Patients.
Lead sponsor
The University of Texas Health Science Center, Houston
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2004
Completion date
March 31, 2010
Enrollment
76 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections